Leciva's First Quarter 1996
- Leciva, a Prague-based pharmaceuticals and vitamins producer, recorded gross profit of 222 million koruna ($8 million) in the first quarter of 1996. Sales were 1.33 billion koruna, reports the CTK news agency's Business News. The added value of the firm's production was 27% higher than in the same period in 1995.
Full-year net profits in 1995 were 310 million koruna on sales of 4.3 billion koruna. 70% of sales were made in the Czech Republic, with exports mainly to Slovakia, Russia, the Ukraine, Hungary and Poland. The firm manufactures 250 different types of drugs, including antibiotics, chemotherapeutics, analgesics, vitamins and hormones. The company's board has called for a quickening of the pace of its privatization, saying that the firm requires this to carry out its development plan.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze